S. 3506 (112th): Ethical Pathway Act of 2012

Aug 02, 2012 (112th Congress, 2011–2013)
Died (Referred to Committee)
Bernard “Bernie” Sanders
Senator from Vermont
Read Text »
Last Updated
Aug 02, 2012
7 pages
Related Bills
S. 3921 (111th) was a previous version of this bill.

Referred to Committee
Last Action: Sep 29, 2010


This bill was introduced on August 2, 2012, in a previous session of Congress, but was not enacted.

Introduced Aug 02, 2012
Referred to Committee Aug 02, 2012
Full Title

A bill to eliminate requirements to undertake duplicative clinical testing of new pharmaceutical drugs, vaccines, biological products, or medical devices, when such duplication is inconsistent with relevant ethical norms.


No summaries available.


Senate Health, Education, Labor, and Pensions

The committee chair determines whether a bill will move past the committee stage.

Primary Source

THOMAS.gov (The Library of Congress)

GovTrack gets most information from THOMAS, which is updated generally one day after events occur. Activity since the last update may not be reflected here. Data comes via the congress project.


Get a bill status widget for your website »


Click a format for a citation suggestion:


S. stands for Senate bill.

A bill must be passed by both the House and Senate in identical form and then be signed by the president to become law.

The bill’s title was written by its sponsor.

GovTrack’s Bill Summary

We don’t have a summary available yet.

Library of Congress Summary

The summary below was written by the Congressional Research Service, which is a nonpartisan division of the Library of Congress.

Ethical Pathway Act of 2012 - Directs the Commissioner of Food and Drugs (FDA) to establish a mechanism by which an applicant to sell any new pharmaceutical drug, vaccine, biologic product, or medical device that requires regulatory approval by the Secretary of Health and Human Services (HHS) (regulated product) may request a cost-sharing arrangement under which the applicant shall:
(1) verify that intended clinical investigations involving humans or vertebrate animals have not been performed or initiated by another person;
(2) make reasonable efforts to obtain voluntary agreements to use existing evidence regarding the safety and efficacy of new pharmaceutical drugs or biological products used to obtain marketing approval for use in humans or vertebrate animals (regulatory test data); and
(3) notify the Commissioner if there is a failure to reach a voluntary agreement, at which point the Commissioner shall ask the parties to agree to binding arbitration to determine the reasonable and fair fee for relying upon relevant regulatory test data.
Permits such applicant to request such arrangement if, but for the arrangement:
(1) the applicant would be required to conduct clinical investigations involving human subjects that violate Article 20 of the Declaration of Helsinki on Ethical Principles for Medical Research Involving Human Subjects in order to obtain regulatory approval of the regulated product, or
(2) the duplication of the clinical investigations required for such application would violate other applicable ethical standards concerning the testing of products on humans or other vertebrate animals.
Requires the fee for reliance by the applicant on such regulatory test data to be determined after considering:
(1) the actual out-of-pocket costs of the applicable clinical investigations;
(2) the risks of the investigations;
(3) any federal grants, tax credits, or other subsidies;
(4) the expected share of the global market for the product involved; and
(5) the amount of time the holders of the relevant applications or licenses have benefited from exclusive rights and the cumulative revenue earned on the products that relied upon the data at issue.
Directs the Secretary to adopt procedures and rules under which sufficient information about costs and fees will be made public.

House Republican Conference Summary

The summary below was written by the House Republican Conference, which is the caucus of Republicans in the House of Representatives.

No summary available.

House Democratic Caucus Summary

The House Democratic Caucus does not provide summaries of bills.

So, yes, we display the House Republican Conference’s summaries when available even if we do not have a Democratic summary available. That’s because we feel it is better to give you as much information as possible, even if we cannot provide every viewpoint.

We’ll be looking for a source of summaries from the other side in the meanwhile.

Use the comment space below for discussion of the merits of S. 3506 (112th) with other GovTrack users.
Your comments are not read by Congressional staff.

comments powered by Disqus